AstraZeneca (NASDAQ: AZN) reported Q2 EPS of $2.15, $1.16 better than the analyst estimate of $0.99. Revenue for the quarter came in at $11.42 billion versus the consensus estimate of $11.02 billion.

The Company reiterates guidance for FY 2023 at CER, based on the average foreign exchange rates through 2022.

For earnings history and earnings-related data on AstraZeneca (AZN) click here.